HF
AKBA icon

HRT Financial’s Akebia Therapeutics AKBA Stock Holding History

HRT Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Sell
976,937
-642,399
-40% -$883K ﹤0.01% 1865
2025
Q4 		$2.61M Buy
1,619,336
+1,594,539
+6,430% +$3.34M 0.01% 1131
2025
Q3 		$67K Buy
+24,797
New +$82.5K ﹤0.01% 2566
2025
Q2 		– Sell
-46,726
Closed -$89K – 2533
2025
Q1 		$89K Buy
+46,726
New +$95.4K ﹤0.01% 2167
2024
Q1 		– Sell
-15,094
Closed -$18K – 2232
2023
Q4 		$18K Buy
+15,094
New +$15.4K ﹤0.01% 2044
2023
Q2 		– Sell
-148,681
Closed -$83K – 2393
2023
Q1 		$83K Buy
+148,681
New +$114K ﹤0.01% 2083
2022
Q4 		– Sell
-23,453
Closed -$7K – 2419
2022
Q3 		$7K Sell
23,453
-1,080,284
-98% -$424K ﹤0.01% 2565
2022
Q2 		$389K Buy
1,103,737
+1,078,469
+4,268% +$453K ﹤0.01% 1848
2022
Q1 		$18K Sell
25,268
-353,300
-93% -$756K ﹤0.01% 2845
2021
Q4 		$855K Buy
+378,568
New +$1.03M ﹤0.01% 1265
2021
Q3 		– Sell
-62,446
Closed -$236K – 3228
2021
Q2 		$236K Sell
62,446
-201,535
-76% -$678K ﹤0.01% 2295
2021
Q1 		$893K Buy
+263,981
New +$951K 0.01% 1262
2019
Q4 		– Sell
-16,367
Closed -$64K – 1119
2019
Q3 		$64K Buy
+16,367
New +$70.1K ﹤0.01% 1287

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HRT Financial's AKBA Position: Q1 2026 in Review

HRT Financial reduced its Akebia Therapeutics (AKBA) stake by 40% in Q1 2026, selling an estimated $883K and leaving 976,937 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

HRT Financial first reported a position in AKBA in Q3 2019 and has held it in 13 quarters since. The position peaked at $2.61M in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • HRT Financial held 976,937 shares of Akebia Therapeutics worth $1.36M as of Q1 2026.
  • HRT Financial sold 642,399 Akebia Therapeutics shares in Q1 2026, an estimated $883K.
  • Akebia Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #1865 holding.
  • HRT Financial first reported a position in Akebia Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • HRT Financial's Akebia Therapeutics position peaked at $2.61M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.